Now I have read the paper in full. Let me produce the consolidated meta-review.

---

## Summary

The paper proposes *conformalized survival counterfactual prediction*, a calibration procedure for constructing Lower Predictive Bounds (LPBs) on counterfactual survival times under general right-censored data. The core idea is to restrict calibration to uncensored observations in the treatment group of interest and correct for the resulting selection bias via importance weights, reducing the problem to weighted conformal prediction (Lei & Candès, 2021). The paper claims this yields an *exact* marginal coverage guarantee — contrasted with the PAC-type guarantees of Gui et al. (2024) and Davidov et al. (2025) — and establishes a doubly robust property under misspecification of either the weight estimator or the quantile regressor.

---

## Strengths

- **Novel, verifiable upper-bound argument (Equation 1).** The chain of inequalities in Section 4.1 establishes that controlling the weighted miscoverage over uncensored observations upper-bounds the overall population miscoverage. Step (iii) — that P(T ≤ c | X, W) ≤ P(T ≤ c | e=1, X, W) for relevant thresholds — is the critical and correct insight that makes the guarantee possible without requiring censored calibration data.

- **Doubly robust property (Theorem 4.2, Equation 6–7).** The paper formally proves that asymptotic coverage is preserved if either the weight estimator γ̂(x) or the counterfactual quantile estimator q̂_τ^(w)(x) is consistently estimated, not both simultaneously. This guards against common model misspecification and is not previously shown in the survival counterfactual setting.

- **Empirical validity with informative bounds.** Across all six synthetic settings in Figure 1, the proposed method achieves empirical coverage nearest the 90% nominal level while simultaneously producing higher relative LPBs than naive, focused, and fused baselines. Figure 3 further demonstrates that coverage is maintained under heavy outlier contamination, where PAC-type methods (Focus, Fused) systematically under-cover.

- **Clinically grounded real-data application.** On a 541-patient lung cancer dataset, LPBs under VMAT vs. IMRT (Figure 4) and across known prognostic factors such as tumor stage, KPS, and radiomic features (Figure 5) align directionally with established clinical evidence, indicating the method captures meaningful survival information.

---

## Weaknesses

### Fatal
None.

### Major

- **"Exact" framing is imprecise in a consequential way.** The abstract and introduction repeatedly describe the guarantee as "exact" or "distribution-free exact." However, Theorem 4.1 (Equation 4) explicitly gives:
  $$\mathbb{P}(T(w) \geq \tilde{L}_{N,n}^{(w)}(X)) \geq 1 - \alpha - \tfrac{1}{2}\,\mathbb{E}_{X \sim \mathbb{P}_{X|W=w,e=1}}[|\tilde{\omega}(X) - \omega(X)|],$$
  which is an *approximate* finite-sample bound that degrades with weight estimation error — not "exact" in the sense that standard conformal prediction (with exchangeable data and no estimation) is exact. Exact guarantees are only obtained asymptotically under Theorem 4.2 (Condition A1 or A2), which requires consistent weight or quantile estimation. The paper should replace "exact" in the abstract and introduction with a precise description: the finite-sample guarantee controls expected miscoverage up to a weight-estimation error term, and asymptotically recovers exact coverage. The distinction from PAC-type methods is that this paper controls *expected* (marginal) miscoverage rather than providing high-probability-over-calibration-sample coverage — which is a genuine and meaningful advantage — but this advantage is elided by the imprecise "exact" label.

### Minor

- **Setting 6 undercoverage unexplained.** The paper states: "the average coverage rate of our method slightly falls below 1 − α in setting 6" (Section 5.1). For a paper whose headline claim is an exact (or near-exact) coverage guarantee, an empirical coverage shortfall in one of the six test settings — even if small — requires explanation. The characteristics of Setting 6 (censoring rate, treatment imbalance) are confined to Appendix C.1 (stripped by parser), leaving the reader unable to assess whether this represents an edge case or a common scenario. A brief in-text explanation of what makes Setting 6 difficult would resolve this.

- **No empirical analysis of coverage quality versus censoring rate.** Algorithm 1, Step 3 restricts calibration to $\mathcal{I}_{\text{cal}}^{(w)} = \{i: W_i = w, e_i = 1\}$. In high-censoring clinical settings — the paper's primary motivation — this can dramatically reduce effective calibration set size (e.g., 40% treatment × 40% uncensored = 16% of all calibration samples). The Discussion acknowledges that "high censoring rates may lead to inaccurate estimation of γ(x)" but provides no empirical analysis of how coverage or LPB informativeness degrades as censoring rate increases. Given the six synthetic settings presumably vary censoring rates, reporting this relationship would substantially strengthen the paper's practical guidance.

- **Causal interpretation of LPB comparisons in real data is mildly overclaimed.** Section 5.2 states: "the result shows a higher median LPB than those treated under intensity modulated radiation therapy (IMRT), which is consistent with VMAT's better clinical benefits." While the LPBs are statistically valid coverage bounds under the stated assumptions, directly interpreting LPB magnitude differences across treatment groups as treatment effect evidence requires the additional causal assumptions to hold in the real dataset. The paper should note this explicitly.

### Trivial

- **τ optimization and calibration data dependence.** The paper notes (Section 4.1) that τ^*(x) is optimized to maximize L̃_{N,n}^{(w)}(X, τ) and states coverage holds for any τ. The experimental setup (Figure 1 caption) mentions a validation fold separate from calibration, suggesting τ may be selected on held-out validation data — but Algorithm 1 does not mention this explicitly. In small-data regimes, clarifying that τ optimization uses a held-out validation set would eliminate any doubt about circular dependence on the calibration data used to compute c_{1-α}^(w)(τ).

---

## Nice-to-Haves

- A formal comparison theorem or proposition explicitly characterizing the conditions under which the proposed marginal coverage bound dominates the PAC-type bound of Davidov et al. (2025) would sharpen the paper's positioning and replace informal "exact vs. PAC" language with a rigorous head-to-head characterization.

- A censoring-rate sensitivity experiment reporting coverage and LPB as censoring increases from ~20% to ~80% (holding other factors fixed) would provide direct practical guidance on when the method is reliable and where it starts to degrade.

- The Discussion mentions that setting 6 falls short; an in-text characterization of the challenging regimes (e.g., extreme censoring or treatment imbalance) would better inform practitioners.

---

## Removed Points

*These points are flagged to be removed; treat them with caution.*

- **Harsh Critic: "Logical connection not explicit in main text" (Section 3/4 boundary).** Removed. The paper explicitly states after equation (1): "Through the upper bound in (iv), note that it is sufficient for the LPB T̃_{N,n}^{(w)}(X,τ) to satisfy the coverage guarantee for P_X × P_{T̃|W=w,e=1,X}." The logical connection is present in the main text; the critic's claim that readers must reconstruct it themselves is incorrect.

- **Harsh Critic: "Missing Candès et al. (2023) as a numerical baseline."** Removed. The paper clearly scopes to *general* right-censored data, while Candès et al. (2023) applies only to Type-I right-censored data (where C is known). The exclusion is justified by methodological incompatibility, not an oversight.

- **Harsh Critic: "Six settings' characteristics relegated to appendix."** Removed. This is a formatting/length constraint and the appendix reference is explicit. The underlying concern about setting 6 is retained as a Minor weakness in its verifiable form.

- **Harsh Critic: "Theorem 4.2 A2(ii) non-standard condition that doesn't match doubly-robust intuition."** Demoted to Trivial / removed from main weaknesses. The condition in equation (5) — lim[ε_N(X)/γ̂(x)] = lim[ε_N(X)/γ(x)] — is a technical regularity condition that ensures quantile estimation errors are asymptotically unaffected by weight estimation. While non-standard, it is a legitimate regularity condition appropriate for an asymptotic result. The paper correctly notes its practical import. This does not threaten the core claim.

- **Harsh Critic: "Covering PAC methods may be conservative."** Removed. The paper's own claim is about expected marginal miscoverage control vs. high-probability-over-sample coverage. The comparison is methodologically fair and the paper's advantage is real.

- **Strength Finder: "Optimised τ-selection yields informative LPBs" as a core strength.** Downgraded to supporting / nice-to-have. Table 1 shows τ^* gives only marginal improvement over τ = α (e.g., 0.803 vs. 0.778 at α=0.1). This is consistent with the paper's own observation that "the quantile regression model is well trained," but does not represent a major contribution beyond the calibration procedure itself.

---

## Novel Insights

The key insight of the paper — that restricting calibration to uncensored, treated observations and applying importance weights defined by γ(x) = P(W=w, e=1|X) is sufficient to control population-level coverage via a valid upper bound — is technically clever and fills a real gap between Type-I censoring methods (Gui et al., Candès et al.) and fully general right-censored counterfactual bounds. The doubly robust extension is a practically important property that goes beyond simple reweighting. The outlier robustness experiment (Figure 3) provides an illuminating demonstration that PAC-type guarantees can fail precisely when the data has tail irregularities, reinforcing why expected marginal coverage control matters in clinical settings.

---

## Suggestions

1. **Revise "exact" language throughout.** Replace "exact miscoverage guarantee" in the abstract and introduction with a precise statement distinguishing: (a) the finite-sample bound of Theorem 4.1 (valid up to weight estimation error), and (b) asymptotic exactness under Theorem 4.2. This accurately frames the contribution and pre-empts misreading.

2. **Explain Setting 6 in the main text.** Add 1–2 sentences in Section 5.1 identifying the characteristics of Setting 6 (censoring rate, treatment imbalance, or sample size per subgroup) that cause slight undercoverage, and note whether this is expected from theory.

3. **Add a censoring-rate sensitivity figure.** Plot empirical coverage and LPB against censoring rate (e.g., 20%–80%) to provide direct guidance on the operating range of the method.

4. **Clarify τ optimization in Algorithm 1.** State explicitly in Algorithm 1 (or its caption) that τ^* is selected on the validation fold, not the calibration fold, to avoid any ambiguity about circular data usage.

5. **Soften causal language in Section 5.2.** Qualify the clinical interpretation with a sentence acknowledging that comparing LPBs across treatment groups requires the ignorability assumption to hold in practice, and that this analysis is observational.

---

## Evaluation on Key Axes

- **Originality**: Moderate-to-good. Combines weighted conformal prediction, causal inference under strong ignorability, and survival analysis in a novel configuration. The key inequality chain (equation 1) is the original technical contribution. The doubly robust extension is a meaningful addition.
- **Importance of Research Question**: High. Personalized survival predictions under different treatments with valid uncertainty quantification is directly relevant to clinical decision-making.
- **Claims Well-Supported**: Mostly yes, with the caveat that "exact" is imprecisely used. Theorems 4.1 and 4.2 do support the core claims with appropriate qualification. Setting 6 undercoverage is a minor empirical gap.
- **Soundness of Experiments**: Good. Six synthetic settings with 50 trials, multi-treatment extension, outlier robustness, and real clinical data. The lack of censoring-rate sensitivity analysis is a gap.
- **Clarity of Writing**: Good overall; the logical structure of Section 4 is clear. Precision could be improved around the guarantee type.
- **Value to Research Community**: High for survival analysis, causal inference, and conformal prediction communities.

---

MY FINAL SCORE: <score>7.0</score>
MY FINAL DECISION: <decision>Accept</decision>

<subscores>
<originality>3</originality>
<importance>4</importance>
<claims_supported>3</claims_supported>
<soundness>4</soundness>
<clarity>3</clarity>
<community_value>4</community_value>
</subscores>